Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Tapestry, Inc. — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Tapestry, Inc. trades at $140.22 (market cap $28.43B). The key difference: Alnylam Pharmaceuticals, Inc. is the larger of the two by market cap, and Tapestry, Inc. pays a 1.14% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | TPR | |
|---|---|---|
Market Cap | $39.89B | $28.43B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $160.49 |
52-Week Low | $278.09 | $95.69 |
Enterprise Value | $38.15B | $31.29B |
Dividend Yield | — | 1.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
TPR trades at $140.73, up 0.57% today, with a bearish technical signal but strong analyst support. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS expected at $1.24. Valuation ratios are elevated (P/E 42.91, P/B 41.67), though profitability metrics like a 76.18% gross margin and 55.74% ROE remain robust. Recent news highlights digital growth and Gen Z engagement, with a $0.40 dividend paid in June 2026.
The outlook is mixed: bullish analyst consensus ($184.14 price target, 75.61% buy ratings) contrasts with technical bearishness and a high debt load. Key risks include sensitivity to consumer spending and execution of growth initiatives. Upside hinges on sustained earnings beats and margin expansion, while debt management and competitive pressures pose challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
